Arg-Pro-Hyp-Gly-Phe-
Ser-Pro-Phe-Arg (M.W. 1076.2) C50H73N15O12 [37642-65-2] H. Kato, Y. Matsumura, and H. Maeda, FEBS Lett., 232, 252 (1988). (Original) E.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Springer-Verlag, Berlin, 1970. (Review) E.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Suppl., Springer-Verlag, Berlin, 1979. (Review) * The biological activity of these peptides is examined by the Division of Pharmacology, Peptide Institute, Inc.
Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1076.2) C50H73N15O12 [37642-65-2] H. Kato, Y. Matsumura, and H. Maeda, FEBS Lett., 232, 252 (1988). (Original) E.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Springer-Verlag, Berlin, 1970. (Review) E.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Suppl., Springer-Verlag, Berlin, 1979. (Review) * The biological activity of these peptides is examined by the Division of Pharmacology, Peptide Institute, Inc.
![[Hyp3]-Bradykinin (0.5 mg vial) - PBK-4193-v - 1 Ea - Peptides International, Inc.](https://partimages.globalspec.com/28/4628/1869628_medium.png)
